Focused on the development of novel medicines to validated anti-cancer and fibrosis targets in areas of unmet need
Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic and then partner. The company’s product development strategy has three interrelated components:
Cancer: RXC004, our lead clinical asset
Build on compelling animal efficacy data to demonstrate safe dose in phase 1 and set-up partnered immuno-oncology (IO) combination programme.
Fibrosis: Take promising anti-fibrotic portfolio into the clinic
Key promising anti-fibrotic programmes that Redx Pharma has in the pipeline are:
Porcupine RXC006: Idiopathic pulmonary fibrosis (IPF)
GI-targeted ROCK: Crohn’s Disease-related fibrosis
ROCK2: Non-alcoholic steatohepatitis (NASH)
Research: Next generation therapies
Preclinical programmes to generate novel development compounds in 18-36 months through rigorous selection of targets strong medicinal chemistry.
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
